Evidence map›Paper›PMID 32513154›Full record

ArticleBMC veterinary research2020

Is clinical effect of autologous conditioned serum in spontaneously occurring equine articular lameness related to ACS cytokine profile?

Patrick Marques-Smith, Anne S Kallerud, Grethe M Johansen, Preben Boysen, Anna M Jacobsen, Karoline M Reitan, Mia M Henriksen, Maria Löfgren, Cathrine T Fjordbakk

Open access · goldAbstract read
In one paragraph

Article in BMC veterinary research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Regenerative Medicine for Equine Musculoskeletal Diseases.Animals : an open access journal from MDPI · 2021
    Review
  15. Article
  16. The Use of Autologous Protein Solution (Pro-StrideVeterinary medicine (Auckland, N.Z.) · 2021
    Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Patrick Marques-SmithDepartment of Companion Animal Clinical Sciences, Faculty of Veterinary Medicine, Norwegian University of Life Sciences, 0102, Oslo, Norway. patrick.pm.smith@nmbu.no.ORCID http://orcid.org/0000-0001-5909-9322
Anne S KallerudDepartment of Companion Animal Clinical Sciences, Faculty of Veterinary Medicine, Norwegian University of Life Sciences, 0102, Oslo, Norway.
Grethe M JohansenDepartment of Food Safety and Infection Biology, Faculty of Veterinary Medicine, Norwegian University of Life Sciences, 0102, Oslo, Norway.
Preben BoysenDepartment of Food Safety and Infection Biology, Faculty of Veterinary Medicine, Norwegian University of Life Sciences, 0102, Oslo, Norway.
Anna M JacobsenDepartment of Companion Animal Clinical Sciences, Faculty of Veterinary Medicine, Norwegian University of Life Sciences, 0102, Oslo, Norway.
Karoline M ReitanDepartment of Companion Animal Clinical Sciences, Faculty of Veterinary Medicine, Norwegian University of Life Sciences, 0102, Oslo, Norway.
Mia M HenriksenDepartment of Companion Animal Clinical Sciences, Faculty of Veterinary Medicine, Norwegian University of Life Sciences, 0102, Oslo, Norway.
Maria LöfgrenDepartment of Biomedical Science and Veterinary Public Health, Swedish University of Agricultural Sciences, 75007, Uppsala, Sweden.
Cathrine T FjordbakkDepartment of Companion Animal Clinical Sciences, Faculty of Veterinary Medicine, Norwegian University of Life Sciences, 0102, Oslo, Norway.
Norwegian University of Life Sciences · NOSwedish University of Agricultural Sciences · SE

Funding

Norges Forskningsråd 589610Swedish/ Norwegian Foundation for Equine Research H1247030
6 · The paper itself

Abstract

backgroundBiologic' therapies, such as autologous conditioned serum (ACS), are gaining popularity in treating orthopaedic conditions in equine veterinary medicine. Evidence is scarce regarding ACS constituents, and large inter-individual differences in cytokine and growth factor content have been demonstrated. The objective of the current study was to investigate the potential association between cytokine and growth factor content of ACS and clinical effect in harness racehorses with spontaneously occurring low-grade articular lameness. Horses received 3 intra-articular injections of ACS administered at approximately 2-week intervals. Lameness evaluation consisting of a trot-up with subsequent flexions tests was performed at inclusion and approximately 2 weeks after the last treatment (re-evaluation); horses were classified as responders when there was no detectable lameness on trot-up and a minimum of 50% reduction in flexion test scores at re-evaluation. Association between clinical outcome (responders vs. non-responders) and age, lameness grades at inclusion (both initial trot-up and after flexion tests), treatment interval, follow-up time and the ACS content of IL-1Ra, IGF-1 and TGF-β was determined by regression modelling.

resultsOutcome analysis was available for 19 of 20 included horses; 11 responded to treatment whereas 8 did not. There was considerable inter-individual variability in cytokine/growth factor content of ACS, and in the majority of the horses, the level of IL-10, IL-1β and TNF-α was below the detection limit. In the final multivariate logistic regression model, ACS content of IGF-1 and IL-1Ra was significantly associated with clinical response (P = 0.01 and P = 0.03, respectively). No association with clinical response was found for the other tested variables.

conclusionsThe therapeutic benefit of ACS may be related to higher levels of IL-1Ra and IGF-1. Our study corroborates previous findings of considerable inter-individual variability of cytokine- and growth factor content in ACS.

Indexed as

AnimalsBiological TherapyCohort StudiesFemaleHorse DiseasesHorsesInjections, Intra-ArticularInsulin-Like Growth Factor IInterleukin 1 Receptor Antagonist ProteinLameness, AnimalMaleProspective StudiesSerumTransforming Growth Factor betaTreatment OutcomeInsulin-Like Growth Factor IInterleukin 1 Receptor Antagonist ProteinTransforming Growth Factor betaBiologic therapiesCytokinesGrowth factorsIntra-articular treatment

Identifiers

PMID32513154
PMCPMC7278142
OpenAlexW3033808245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.